Toward Patient-Centered Drug Development in Oncology

Key Points

Key points are not available for this paper at this time.

Abstract

Regulators and industry continue to prioritize survival-based end points rather than patient-experience end points in cancer-drug development. Yet as patients live longer with cancer, they must increasingly choose among agents with varying efficacy–toxicity balances.

Mark Helpful

Bookmark

Relay

Cite This Study

Ethan Basch (Thu,) studied this question.

synapsesocial.com/papers/6a1d79411e7099f691057cba https://doi.org/https://doi.org/10.1056/nejmp1114649

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers2010 · 150 citations
2Evaluation of the Relationship Between Individual Well-Being and Future Health Care Utilization and Cost2012 · 60 citations
3Methodological Standards and Patient-Centeredness in Comparative Effectiveness Research2012 · 252 citations
4A Review of Patient-Reported Outcome Labels in the United States: 2006 to 20102012 · 128 citations
5Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group1994 · 585 citations

Mark Helpful

Bookmark

Relay